Classic Hodgkin Lymphoma Clinical Trials

25 clinical trials for Classic Hodgkin Lymphoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma — RECRUITING
• Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma — RECRUITING · PHASE2
• MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma — RECRUITING · PHASE2
• Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy — RECRUITING · NA
• Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma — RECRUITING · PHASE2
• Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment — RECRUITING · PHASE2
• A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma — RECRUITING · PHASE1
• ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE2
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma — TERMINATED · PHASE2
• Neurocognitive Assessment in Long-Term Survivors of Lymphoma — NOT_YET_RECRUITING
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] — TERMINATED · PHASE2
• Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma — COMPLETED · PHASE1
• Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience — COMPLETED
• Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE3
• A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies — OTHER · PHASE1
• Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD) — COMPLETED
• Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas — OTHER · PHASE1
• Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma — COMPLETED · PHASE2

Refine this search